Generic Name and Formulations:
Oxytocin 10Units/mL; IV or IM inj.
Par Pharmaceutical, Inc.
Indications for PITOCIN:
Initiation or improvement of uterine contractions in vaginal delivery. Adjunct in abortion. Control of postpartum bleeding.
Induction of labor: individualize. Initially 0.5–1milliunit/minute (see literature); adjust by 1–2 milliunits/minute at 30–60 minute intervals. Usual max at term: 9–10 milliunits/minute. Bleeding: IV, see literature. IM: 10Units after delivery of placenta. Abortion: see literature.
In anteparum use: Cephalopelvic disproportion. Unfavorable fetal position. When surgical intervention necessary. Fetal distress if labor is not imminent. Unsatisfactory progress in presence of adequate uterine activity. Hyperactive or hypertonic uterus. Invasive cervical carcinoma, active herpes genitalis, total placenta previa, vasa previa, cord presentation or prolapse or other cases where vaginal delivery is contraindicated or if predisposition for uterine rupture exists.
Not for elective induction of labor.
Use only in presence of qualified personnel. Monitor intrauterine pressure, fetal heart rate, maternal blood pressure.
Avoid use within 4 hours of prophylactic vasoconstriction with caudal block anesthesia. Avoid cyclopropane anesthetics.
Maternal: anaphylaxis, postpartum or subarachnoid hemorrhage, arrhythmias, fatal afibrinogenemia, nausea, vomiting, premature ventricular contraction, pelvic hematoma, water intoxication, hypersensitivity resulting in uterine hypertonicity, spasm, tetany, or rupture. Fetal: bradycardia, arrhythmias, CNS damage, seizure, low Apgar scores, jaundice, retinal hemorrhage, death.
Single-dose vial (1mL)—25; Multi-dose vial (10mL)—1, 25
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age
- LVAD in Heart Failure Linked to Improved Glycemic Control
- Fundamental Institutional Change Is Needed to Eliminate Sexual Harassment
- Gestational Diabetes Tied to Subsequent Glucose Disorders
- Association Health Plans Can Help Small Businesses Offer Coverage